A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11)
Phase of Trial: Phase III
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Sintilimab (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms Orient-11
- Sponsors Innovent Biologics
- 10 Sep 2018 According to an Innovent Biologics media release, first patient has been dosed in the trial.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting, according to an Innovent Biologics media release.
- 05 Aug 2018 New trial record